NEW YORK and CAESAREA,
Israel, March 20, 2019
/PRNewswire/ -- Global digital therapeutics innovator, DarioHealth
Corp. (NASDAQ: DRIO), announced today the receipt of a license from
Health Canada to sell its Dario™ Blood Glucose Monitoring System
for Lightning power connector-enabled iPhone smart mobile
devices.
iPhone users in Canada,
including those with prior models that use a headphone jack, as
well as those with the Lightning power connector, will now have
access to DarioHealth's acclaimed digital diabetes products and
lifestyle management app features, like glucose level tracking,
real time patient glucose data access for healthcare providers,
carb counting, hypo alerts, amongst other diabetes countering
features.
DarioHealth has marketed the product in Canada exclusively for Apple iOS 6.1 platform
and higher, and for leading Android devices since receiving a
license from Health Canada in May
2015.
With this license, DarioHealth's addressable Canadian market
expands to include the entire iPhone user base.
"Recognizing the importance of access to the entire iPhone
market in Canada, we prioritized
this initiative to meet Health Canada's rigid licensing standards,
and our team worked tirelessly to achieve it," commented
Erez Raphael, DarioHealth's CEO.
"Not only will this access a large segment of new users, but it
will allow our existing Canadian users who have upgraded their
iPhones to reconnect with our life enhancing services."
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ:
DRIO) is a leading global Digital Therapeutics (DTx) company
revolutionizing the way people manage their health across the
chronic condition spectrum. By delivering evidence-based
interventions that are driven by data, high quality software and
coaching, we developed a novel approach that empowers individuals
to adjust their lifestyle in a personalized way. Our Cross
Functional Team operates at the intersection of life sciences,
behavioral science and software technology to deliver highly
engaging therapeutic interventions. Already one of the highest
rated diabetes solutions, its user-centric approach is loved by
tens of thousands of consumers around the globe. DarioHealth is
rapidly moving into new chronic conditions and geographic
markets.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company states
that Health Canada license for iPhone devices opens a significant
market opportunity, it is using forward-looking statements. Readers
are cautioned that certain important factors may affect the
Company's actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect the Company's results
include, but are not limited to, regulatory approvals, product
demand, market acceptance, impact of competitive products and
prices, product development, commercialization or technological
difficulties, the success or failure of negotiations and trade,
legal, social and economic risks, and the risks associated with the
adequacy of existing cash resources. Additional factors that could
cause or contribute to differences between the Company's actual
results and forward-looking statements include, but are not limited
to, those risks discussed in the Company's filings with the U.S.
Securities and Exchange Commission. Readers are cautioned that
actual results (including, without limitation, the timing for and
results of the Company's commercial and regulatory plans for
Dario™) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact:
Joao Mendes-Roter
VP Marketing
joao@mydario.com
+1-914-775-5548
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dariohealth-granted-license-by-health-canada-to-sell-dario-smart-glucose-meters-for-lightning-connector-enabled-iphones-300815558.html
SOURCE DarioHealth Corp.